Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 3-Hour drip beat a 30-Minute one for sick kids?

NCT ID NCT07484633

Disease control Sponsor: Semmelweis University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving antibiotics over 3 hours works better than the usual 30-minute drip for critically ill children (0-17 years) with severe infections. About 110 kids in intensive care will take part. The goal is to see if the longer infusion clears the infection faster and is just as safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 hours to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * paediatric patients (0-17 years of age) with suspected or confirmed bacterial infection who are treated in a PICU or NICU and diagnosed with sepsis with a total Phoenix Sepsis Score ≥2 points, and the infection is clinically probable or confirmed by microbiological culture (e.g. from a blood culture, cerebrospinal fluid, urine, trachea, wound, etc.), excluding contamination; * who are receiving β-lactams including meropenem, piperacillin/tazobactam, cefepime and ceftriaxone; * who received the same β-lactam therapy within 24 hours prior to inclusion or started new β-lactam therapy due to clinical deterioration; * written consent of the parent or guardian is obtained. Exclusion Criteria: * palliative care patients; * patients participating in other drug trials; * patients with impaired renal function if dosing modification is required (estimated Glomerular Filtration Rate \[eGFR\]\<50 mL/min/1.73m2 for meropenem, cefepime, and piperacillin/tazobactam; eGFR\<10 mL/min/1.73m2 for ceftriaxone); * patients undergoing plasmapheresis (TPE); * patients undergoing extracorporeal therapy (continuous kidney replacement therapy \[CKRT\] or extracorporeal membrane oxygenation \[ECMO\]); * β-lactam allergy; * patients admitted from another institution or department who have been on the same β-lactam treatment for more than 24 hours; * pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Beta lactams are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Beta lactams Infection NICU PICU Sepsis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pediatric Center (Bókay Street Department), Semmelweis University

    Budapest, 1083, Hungary

  • Pediatric Center (Tűzoltó Street Department), Semmelweis University

    Budapest, 1094, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.